Top intervention news from August

Cardiology Today's Intervention compiled a list of the top news posted in August. Last month, readers were most interested in percutaneous mitral valve repair, catheter-directed thrombolysis for pulmonary embolism, news from the European Society of Cardiology Congress and more.

See below for links to the full articles on Healio.com/Intervention.

MITRA-FR: MitraClip does not change prognosis in HFrEF , mitral regurgitation

MUNICH — In patients with HF with reduced ejection fraction and secondary mitral valve regurgitation, percutaneous mitral valve repair plus medical therapy offered no advantage over medical therapy alone, according to results of the MITRA-FR trial presented at the European Society of Cardiology Congress. Read more

Catheter-directed thrombolysis reduces complications in acute PE

Among patients with acute pulmonary embolism, ultrasound-assisted catheter-directed thrombolysis was associated with reduced complications, but patients at high risk remained vulnerable to short-term mortality. Read more

Panel favors PFO closure plus antiplatelet therapy for stroke prevention

Younger patients with a patent foramen ovale who have had a cryptogenic ischemic stroke should undergo PFO closure followed by antiplatelet therapy to reduce risk for future stroke, according to clinical practice guideline published in The BMJ. Read more

Early feasibility study of next-generation pericardial TAVR system underway

An early feasibility study is underway to investigate use of a next-generation pericardial transcatheter aortic valve replacement system for treatment of patients with symptomatic, severe aortic stenosis and aortic regurgitation at extreme or high surgical risk, with the first successful U.S. implantations performed at NewYork-Presbyterian/Columbia University Medical Center and MedStar Washington Hospital Center. Read more

GLOBAL LEADERS: Long-term ticagrelor monotherapy not superior to standard DAPT

MUNICH — In patients who undergo PCI, 1 month of combination ticagrelor and aspirin therapy followed by ticagrelor alone was not superior to 1-year standard dual antiplatelet followed by 1-year aspirin monotherapy for reducing deaths or MI over 2 years, according to findings from the GLOBAL LEADERS study presented at the European Society of Cardiology Congress. Read more

CULPRIT-SHOCK: Culprit-only PCI maintains advantage at 1 year for cardiogenic shock, multivessel disease

MUNICH — At 1 year, risk for death or renal replacement therapy was lower among patients with acute MI, cardiogenic shock and multivessel CAD who underwent culprit-lesion-only PCI compared with multivessel PCI, according to new data from the CULPRIT-SHOCK study. The findings were reported at the European Society of Cardiology Congress. Read more